Literature DB >> 23211429

Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption.

A Joseph Bloom1, Sharon E Murphy, Maribel Martinez, Linda B von Weymarn, Laura J Bierut, Alison Goate.   

Abstract

BACKGROUND: Flavin-containing monooxygenases (FMO) catalyze the metabolism of nucleophilic heteroatom-containing drugs and xenobiotics, including nicotine. Rare mutations in FMO3 are responsible for defective N-oxidation of dietary trimethylamine leading to trimethylaminuria, and common genetic variation in FMO3 has been linked to interindividual variability in metabolic function that may be substrate specific.
METHODS: A genetic model of CYP2A6 function is used as a covariate to reveal functional polymorphism in FMO3 that indirectly influences the ratio of deuterated nicotine metabolized to cotinine following oral administration. The association is tested between FMO3 haplotype and cigarette consumption in a set of nicotine-dependent smokers.
RESULTS: FMO3 haplotype, based on all common coding variants in Europeans, significantly predicts nicotine metabolism and accounts for ∼2% of variance in the apparent percent of nicotine metabolized to cotinine. The metabolic ratio is not associated with FMO2 haplotype or an FMO1 expression quantitative trait locus. Cross-validation demonstrates calculated FMO3 haplotype parameters to be robust and significantly improve the predictive nicotine metabolism model over CYP2A6 genotype alone. Functional classes of FMO3 haplotypes, as determined by their influence on nicotine metabolism to cotinine, are also significantly associated with cigarettes per day in nicotine-dependent European Americans (n=1025, P=0.04), and significantly interact (P=0.016) with CYP2A6 genotype to predict cigarettes per day.
CONCLUSION: These findings suggest that common polymorphisms in FMO3 influence nicotine clearance and that these genetic variants in turn influence cigarette consumption.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23211429      PMCID: PMC4583063          DOI: 10.1097/FPC.0b013e32835c3b48

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  43 in total

1.  Deficient C-oxidation of nicotine continued.

Authors:  N L Benowitz; C Griffin; R Tyndale
Journal:  Clin Pharmacol Ther       Date:  2001-12       Impact factor: 6.875

2.  Novel genes identified in a high-density genome wide association study for nicotine dependence.

Authors:  Laura Jean Bierut; Pamela A F Madden; Naomi Breslau; Eric O Johnson; Dorothy Hatsukami; Ovide F Pomerleau; Gary E Swan; Joni Rutter; Sarah Bertelsen; Louis Fox; Douglas Fugman; Alison M Goate; Anthony L Hinrichs; Karel Konvicka; Nicholas G Martin; Grant W Montgomery; Nancy L Saccone; Scott F Saccone; Jen C Wang; Gary A Chase; John P Rice; Dennis G Ballinger
Journal:  Hum Mol Genet       Date:  2006-12-07       Impact factor: 6.150

3.  Population-specific polymorphisms of the human FMO3 gene: significance for detoxication.

Authors:  J R Cashman; B R Akerman; S M Forrest; E P Treacy
Journal:  Drug Metab Dispos       Date:  2000-02       Impact factor: 3.922

4.  Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities.

Authors:  Makiko Shimizu; Hiroshi Yano; Satomi Nagashima; Norie Murayama; Jun Zhang; John R Cashman; Hiroshi Yamazaki
Journal:  Drug Metab Dispos       Date:  2006-12-01       Impact factor: 3.922

5.  Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities.

Authors:  Chang-Shin Park; Ju-Hee Kang; Woon-Gye Chung; Hyun-Gyu Yi; Jae-Eun Pie; Dong-Kyun Park; R N Hines; D G McCarver; Young-Nam Cha
Journal:  Pharmacogenetics       Date:  2002-01

6.  Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10.

Authors:  Sanna Kaivosaari; Päivi Toivonen; Leah M Hesse; Mikko Koskinen; Michael H Court; Moshe Finel
Journal:  Mol Pharmacol       Date:  2007-06-18       Impact factor: 4.436

Review 7.  Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism.

Authors:  John R Cashman
Journal:  Pharmacogenomics       Date:  2002-05       Impact factor: 2.533

Review 8.  Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives.

Authors:  Irfan M Hisamuddin; Vincent W Yang
Journal:  Pharmacogenomics       Date:  2007-06       Impact factor: 2.533

9.  Analysis of [3',3'-d(2)]-nicotine and [3',3'-d(2)]-cotinine by capillary liquid chromatography-electrospray tandem mass spectrometry.

Authors:  Sharon E Murphy; Peter Villalta; Sing-Wei Ho; Linda B von Weymarn
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-06-29       Impact factor: 3.205

Review 10.  Genetic polymorphisms of flavin-containing monooxygenase (FMO).

Authors:  Sharon K Krueger; David E Williams; Mei-Fei Yueh; Sarah R Martin; Ronald N Hines; Judy L Raucy; Colin T Dolphin; Elizabeth A Shephard; Ian R Phillips
Journal:  Drug Metab Rev       Date:  2002-08       Impact factor: 4.518

View more
  14 in total

1.  Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption.

Authors:  Meghan J Chenoweth; Andy Z X Zhu; Lisa Sanderson Cox; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2014-03       Impact factor: 2.089

2.  Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups.

Authors:  Sharon E Murphy; Sung-Shim L Park; Elizabeth F Thompson; Lynne R Wilkens; Yesha Patel; Daniel O Stram; Loic Le Marchand
Journal:  Carcinogenesis       Date:  2014-09-18       Impact factor: 4.944

3.  Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans.

Authors:  Taraneh Taghavi; Gideon St Helen; Neal L Benowitz; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2017-04       Impact factor: 2.089

Review 4.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

5.  The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.

Authors:  A Joseph Bloom; Linda B von Weymarn; Maribel Martinez; Laura J Bierut; Alison Goate; Sharon E Murphy
Journal:  Pharmacogenet Genomics       Date:  2013-12       Impact factor: 2.089

Review 6.  Biosignature Discovery for Substance Use Disorders Using Statistical Learning.

Authors:  James W Baurley; Christopher S McMahan; Carolyn M Ervin; Bens Pardamean; Andrew W Bergen
Journal:  Trends Mol Med       Date:  2018-02-04       Impact factor: 11.951

7.  Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver.

Authors:  Meijuan Xu; Deepak Kumar Bhatt; Catherine K Yeung; Katrina G Claw; Amarjit S Chaudhry; Andrea Gaedigk; Robin E Pearce; Ulrich Broeckel; Roger Gaedigk; Deborah A Nickerson; Erin Schuetz; Allan E Rettie; J Steven Leeder; Kenneth E Thummel; Bhagwat Prasad
Journal:  J Pharmacol Exp Ther       Date:  2017-08-17       Impact factor: 4.030

Review 8.  Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism.

Authors:  Yadira X Perez-Paramo; Philip Lazarus
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-12-29       Impact factor: 4.481

9.  Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption.

Authors:  Andrew W Bergen; Martha Michel; Denise Nishita; Ruth Krasnow; Harold S Javitz; Karen N Conneely; Christina N Lessov-Schlaggar; Hyman Hops; Andy Z X Zhu; James W Baurley; Jennifer B McClure; Sharon M Hall; Timothy B Baker; David V Conti; Neal L Benowitz; Caryn Lerman; Rachel F Tyndale; Gary E Swan
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

10.  Nicotine-N'-Oxidation by Flavin Monooxygenase Enzymes.

Authors:  Yadira X Perez-Paramo; Gang Chen; Joseph H Ashmore; Christy J W Watson; Shamema Nasrin; Jennifer Adams-Haduch; Renwei Wang; Yu-Tang Gao; Woon-Puay Koh; Jian-Min Yuan; Philip Lazarus
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-31       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.